Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
This is a phase 2, randomized, multiple-dose, placebo-controlled study designed to
evaluate the safety, efficacy, and pharmacokinetics (PK) of CSL889 (human hemopexin) when
given intravenously (IV) to adults and adolescents with sickle cell disease (SCD)
experiencing...
Age: 12 years - 66+
Gender: All
Cannabinoids for the Reduction of Inflammation and Sickle Cell Related Pain
A randomized, double blind, study of dronabinol as a palliative agent in the treatment of
pain, inflammation, and other complications of sickle cell disease (SCD).
Age: 18 years - 66+
Gender: All
STRIDE Biorepository
The STRIDE Biorepository is an optional substudy available to participants in "Bone Marrow
Transplantation vs Standard of Care in Patients with Severe Sickle Cell Disease (BMT CTN
1503) (STRIDE)".
Age: 15 - 40 years
Gender: All